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• The early identification of urinary bladder cancer pa- 
tients, who are at a high risk of developing recurrences and 
tumor progression, is of utmost importance, because they re- 
quire a more aggressive therapeutic approach and close fol- 
low-up. The routine use ofnewprognosticators, more specific 
and reliable than the established clinicopathologic factors, is 
therefore mandatory. The present work reviews some of the 
most significant biological tumor markers (cell cycle proteins, 
blood group antigens, tumor suppressor genes, oncogenes, 
CD44 gene transcripts, etc.) defined immunohistochemically 
in bladder cancer patients. It summarises most of the re- 
cently published results of the clinical trials, using these mark- 
ers as predictors of the tumor growth, invasion and metastasis. 
It is also an attempt to highlight the present state of the prob- 
lem, the still existing controversy and some of the hypotheses 
concerning the predictive potential of the recently detected 
tumor markers. 
INTRODUCTION 
• Bladder cancer is the second most prevalent urological 
malignancy in men, accounting annually for approximately 
10 000 deaths in USA (1). Of all newly diagnosed cases 70- 
85% are superficial in stage and so potentially completely cur- 
 
able. However, 50-80% of all superficial bladder tumors (SET) 
recur and 25-30% of these recurrences show a higher stage of 
malignancy or metastases (2). 
The early identification of patients, who are at a high risk of 
developing recurrences and tumor progression, is of utmost 
importance, because they require a more aggressive therapeu- 
tic approach, including early total cystectomy. The prognostic 
value of many clinicopathological tumor parameters (stage, 
grade, type, size, multiplicity, location, etc.) has been well 
documented. The results from the quadrant, "mapping", cold- 
cup biopsies, detecting the presence of associated carcinoma 
in situ in normally looking mucosa, provide additional prog- 
nostic information. The quantitative morphometric methods, 
flow cytometry and image analysis, both of which have been 
rapidly introduced in the clinical practice in the last few years, 
seem to be helpful in this aspect. All these prognostic factors, 
either taken alone or in various combinations, appear to be, 
however, insufficient in predicting the tumor behavior in the 
individual patient (3). They provide only a general guide for 
clinical management and none of them gives at present reli- 
able information which specifically correlates with the prog- 
nosis of an individual tumor. Therefore, the routine use of 
new, more specific and effective prognosticators is necessary. 
This need justifies the clinical application of immunohis- 
tochemical methods, defining biological tumor markers with 
a strong predictive value. 
  
  
My main objective here is to review recent papers discussing 
the prognostic role of the most significant biological markers 
for predicting recurrences, tumor progression and patient sur- 
vival in SET. 
In our summing up of the literature, nine main groups of bio- 
logical tumor markers were clearly distinguished. They will be 
reviewed in the same order as they are presented in Table 1 
(see also Table 2 for some abbreviations used in evaluating tu- 
mor stage and grade). 
Table 1. Biological market's in bladder tumors 
Cell cycle markers 
Tumor-associated antigens 




Oncogenes and tumor suppressor genes 
Genetic abnormalities 
CD44 gene transcripts 
Table 2. Tumor stage and grade according to the clas- 
sification of the International Union against Cancer 
Stage/grade    Abbreviations 
 
CELL CYCLE MARKERS 
•         Bromodeoxyuridine test 
Bromodeoxyuridine (BrdU), applied intravenously 3 to 6 h 
prior to transurethral resection of bladder tumors, maybe used 
as an in vivo test for determining the fraction of tumor cells in 
S phase of the cell cycle (4). The mean labelling index corre- 
lated with the tumor stage and grade. Moreover, the SBT that 
recurred during the follow-up period had a mean labelling 
index (at diagnosis) of 8.4 %, whereas the tumors that did not 
recur had a mean labelling index of 3.4 %. These data suggest 
that the in vivo determination of BrdU uptake in SBT may be 
useful in predicting which tumors are likely to recur follow- 
ing resection and so rationalising both the time to follow-up 
and intravesical chemoprophylaxis. 
BrdU labelling cell index status was the third in significance 
prognostic factor in the study of Tachibana etal (5). Patients 
with low BrdU labelling cell index rumors demonstrated a 98% 
3-year survival rate, compared to 42.9 % for those with high- 
grade tumors. 
•         Proliferating cell nuclear antigen 
Proliferating cell nuclear antigen (PCNA) is a protein with a 
molecular weight of 36 kD. It is detected in the proliferating 
cells and serves as a marker of the tumor growth. The fraction 
of PCNA positive nuclei is related to a variety of the known 
prognostic factors, such as stage, grade, and DNA ploidy (6,7). 
In pTa-pTl tumors, the fraction of PCNA-positive nuclei pre- 
dicts tumor progression and patient survival. In a multivari- 
ate survival analysis, PCNA-positive nuclei show independent 
predictive value and may be used as a significant prognostic 
variable of patient outcome. Patients with PCNA indices above 
the median level (12 %) have shown a worse prognosis. The 
measurement of PCNA labelling index in bladder cancer may 
thus prove to be an objective and quantitative assay of biologi- 
cal aggressiveness and may provide significant prognostic in- 
formation. 
•         Ki67 antigen 
The monoclonal antibody Ki67 recognises a cell cycle-related 
nuclear antigen revealed in actively dividing cells. Ki67 reac- 
tivity has been shown to correlate with conventional prognos- 
tic indicators, such as tumor stage and grade, in bladder can- 
cer patients (8). Limas et al (9) evaluated the proliferation ac- 
tivity of urothelial neoplasms, comparing two proliferation 
indices: the percentage of nuclei labelled by BrdU (BrdU in- 
dex) and the percentage of nuclei expressing Ki67 antigen 
(Ki67 index). These were very low in the urothelium of the 
normal controls. Non-invasive SBT had increased BrdU and 
Ki67 indices, but both were below those of the invasive tumors. 
In addition, the number of Ki67-positive cells in G2 SBT might 
be an useful aid in separating those with a favourable progno- 
sis from those with a poor clinical outcome (10). These authors 
also found a significant difference in Ki67 score between 
pTaG2 and pT!G2 SBT. 
TUMOR-ASSOCIATED ANTIGENS 
• Tumor-associated markers defined by monoclonal an- 
tibodies have proven useful to phenotype bladder tumors. Us- 
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ing multiparameter flow cytometry to analyse simultaneously 
DNA content and the expression of surface glycoproteins de- 
fined by monoclonal antibodies T16, Tm5, T43 and T138 (11), 
it was found that T138 antigen expression is a better single 
indicator of cancer progression and patient survival than was 
DNAploidy status (12). The results suggest that simultaneous 
flow cytometry measurements of DNA and surface antigens 
may better assess the malignant course of human bladder tu- 
mors. 
Monoclonal antibodies (10D1,7C12,6D1,3C6,C4 andE7) di- 
rected against bladder tumor cells were tested using flow 
cytometry (13). Analysis of DNA content revealed two groups 
of patients, with unimodal andbimodal profiles. All cells from 
Gl tumors (from the first group) were labelled with 10D1 and 
6D1 antibodies. G3 tumor cells were labelled with C4 and E7 
antibodies and most of them were with a bimodal DNA profile. 
•        CA-50 antigen 
Monoclonal CA-50 antibody is an useful tumor marker in gas- 
trointestinal carcinoma. It was also tested in bladder cancer 
patients (14). The recurrence rate was higher in patients with 
raised levels of CA-50 antigen than those with normal levels 
of this antigen. The CA-50 antigen expression also correlated 
inversely with tumor stage, papillary status, grade of differen- 
tiation, and tumor progression (15). DNA ploidy and CA-50 
antigen expression tested in combination strongly predicted 
patient survival. In multivariate analysis using Cox's propor- 
tional regression hazards model, CA-50 antigen expression 
showed an independent prognostic value in pTa andpTl SET. 
•        MCA  
It was established that the higher the MCA positivity and the 
lower the CA-50 positivity, the worse the prognosis was in 
bladder cancer patients (16). The use of these tumor markers 
in combination predict survival better than their use separately. 
•         Transferrin receptor 
It is not possible to demonstrate the transferrin receptors (TFR) 
in normal bladder mucosa, except in the proliferating cells of 
the basal layer. TFR activity in malignant tissue, however, 
correlates well with the histological grade and the pathologi- 
cal stage of the tumor (17). 
•        CathepsinB 
There is some evidence that cathepsin B (CB), a lysosomal 
endoproteinase, is associated with tumor invasion. CB immu- 
noreactivity in neoplastic cells revealed a strong correlation 
with both grade and invasion beyond the lamina propria (18). 
Most low-grade papillary tumors display a granular cytoplas- 
mic staining pattern in contrast to high-grade tumors, in which 
diffuse staining is present in the cytoplasm. Strong tumor cell 
CB staining is more frequent among recurrent SBT than in 
patients who remain disease-free. The levels and/or distribu- 
tion of CB may be of potential value in defining clinically 
aggressive tumor subsets. 
•         Epithelial membrane antigen 
The epithelial membrane antigen immunostaining correlated 
significantly with patient survival and might provide an addi- 
tional prognostic information (19). 
•         Laminin and type IV collagen 
Laminin, type IV collagen, heparan sulphate proteoglycan 
(perlecan), and nidogen are the main molecular components 
of the basal lamina (BL), including that of the urothelial cells. 
Homotypic and heterotypic interactions between these macro- 
molecules ensure the BL integrity. During tumor cell growth 
and dissemination, these relationships become modulated. 
Invasion of a carcinoma involves the degradation and pen- 
etration of the epithelial BL. This phenomenon might be used 
for histopathologic evaluation of bladder neoplasms. The 5- 
year survival rate of patients having tumors with an inter- 
rupted or absent BL was significantly lower and the rate of 
progression was greater than that of patients with an intact 
BL, as revealed by immunohistochemical staining of laminin 
and type IV collagen (20). 
Given the current concept that BL is involved in tumor progres- 
sion and invasion, it appears reasonable to be tested whether 
other BL molecules, such as perlecan (21) and nidogen, as well 
as some BL-bound growth factors, such as basic fibroblast 
growth factor, may serve as prognostic markers in SBT. 
•         E-cadherin 
E-cadherin, an adhesion molecule of homotypic cell junctions, 
has been shown to behave like an invasion suppressor gene in 
vitro. This may explain the inverse relation between expres- 
sion of E-cadherin and tumor grade that has been found in 
certain cancers. In normal urothelium, E-cadherin is expressed 
homogeneously with a typical membranous staining at cell-cell 
borders. Decreased E-cadherin expression in bladder tumors 
correlates with both increased grade and stage and with shorter 
survival (22). E-cadherin expression may serve as a helpful 
marker of the clinical aggressiveness of bladder tumors, but it 
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•         Autocrine motility factor receptor 
Otto et al (23) also confirmed, that the down-regulation of E- 
cadherin might identify the high-risk patients in relation to 
tumor progression and death of bladder cancer. Parallel to E- 
cadherin, these authors studied the autocrine motility factor 
receptor (gp78) expression and found that the negative ex- 
pression was associated with a low risk of clinical progression 
in the SET patient group. The dual use of these two antigens 
may improve early diagnosis of high-risk bladder cancer pa- 
tients and influence treatment decisions. 
•         HLA-DR antigen 
The expression of HLA-DR antigen in bladder cancer cells cor- 
relates with tumor grade, stage, lymphatic and venous invasion 
and may be regarded as an independent prognostic factor of tu- 
mor growth and progression (24). The 10-year survival of blad- 
der cancer patients with "many" DR-CC (more than 100 cells 
on high power field) was significantly higher than those pa- 
tients, whose tumors were negative for DR-CC (25). 
BLOOD GROUP ANTIGENS 
•        ABH blood group antigens 
ABH blood group antigens (BGAg) are carbohydrate that may 
be detected on the surface of erythrocytes and some other hu- 
man cells, including urothelial cells. Bladder tumor cells lose 
these antigens in the process of malignant dedifferentiation, 
and this deletion correlates with the stage, grade and tumor pro- 
gression (1,26,27). Invasive tumors and carcinoma in situ show 
ABH BGAg deletion which is also demonstrated in SET that 
progress to a higher stage (28). ABH BGAg expression pro- 
vides more valuable prognostic information than the tumor 
grade in relation to recurrences. Both the mean disease-free 
interval and the recurrence rate in BGAg-negative tumors are 
significantly higher than in BGAg-positive tumors (29-31). 
The 10-year survival rate of patients with BGAg-positive tu- 
mors is 74.3 %, whereas that of BGAg-negative tumors is 
46.5%, the difference being statistically significant. Multivari- 
ate analysis of large numbers of patients confirms that ABH 
BGAg deletion is the most significant prognostic factor in re- 
lation to tumor progression, and is not influence by the rest of 
the clinicopathologic factors (28,29,32-35). 
•         Lewis antigens 
The close biosynthetic and structural similarities between the 
ABH and Lewis BGAg made some authors search for similar 
relationships between the expression of Lewis substances and 
the progression of bladder cancer, as was found in ABH BGAg. 
Accordingly, it was shown that 94 % of normal mucosa speci- 





 (36). Abnormal patterns of Lewis reactivity < 
were observed in 43 % of G3 and in 14 % of Gland G2 blad- 
der tumors. Although there was no direct correlation between 
ABH and Lewis antigen expression, all bladder tumors which 
had abnormally low reactivity for these antigens were of high- 
grade and invasive, the expression of BGAg A and Le
a
 only 
having a predictive value in cases of SET (37). However, this 
test could not predict independently the poor disease outcome. 
Thomsen-Friedenreich antigen 
The expression of ABH BGAg precursor, Thomsen-Frieden 
reich antigen (T-antigen), may be abnormal or absent in a 
variety of bladder tumors. This is a more common finding in 
non-invasive, low-grade tumors having worse prognosis in re- 
lation to recurrences than in non-invasive, low-grade tumors 
with a low risk for recurrences (38). The abnormal expression 
of T-antigen correlates significantly with the tumor progres- 
sion and might serve as an independent prognostic factor (35). 
T-antigen expression may also be used as a predictive test for 
evaluating the response of bladder tumors to treatment with 
BCG and interleukin-2 (39). The overall response rate to BCG 
and interleukin-2 treatment in patients with T-antigen-posi- 
tive and T-antigen-negative tumors is found to be 100 % and 
33 %, respectively.  
GROWTH FACTORS 
•         Epidermal growth factor receptors 
The epidermal growth factor (EGF) is detected in high con- 
centrations in the urine, and its receptor, EGFR, may be re- 
vealed in urothelial bladder cancer. Preliminary data have in- 
dicated that assessment of EGFR status is a method of further 
subclassifying bladder cancer in relation to disease outcome. 
A strong positive reaction to EGFR is found almost in a half 
of the examined bladder tumors. Multivariate analysis has 
shown that such cases have a significantly worse prognosis in 
relation to recurrences, progression and tumor-related death 
(12,40,41). Besides, EGFR was confirmed to be an indepen- 
dent predictor of survival and stage progression (42). Most 
probably EGFR overexpression is not an early, but a late event 
in the process of malignant evolution and is usually associ- 
ated with genetic instability. Further studies are necessary in 
order to prove convincingly that EGFR analysis gives a more 
precise prognostic information than the established prognos- 
ticators. 
ENZYME ACTIVITY 
•        The activities of phosphofractokinase (PFK), oc-glyce- 
rolphosphate dehydrogenase (a-GPDH), and phosphohexose 
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isomerase (PHI) in tissue samples of bladder tumors showed 
significant decreases with increased stage and grade (43). 
Decreased activity of the enzymes PFK, PHI and lactate dehy- 
drogenase was associated with significantly higher risk of tu- 
mor progression (44). In effect, it was suggested that the mea- 
surements of en2yme activity in SET might help selecting in- 
dividual patients with a high risk of progression, for adjuvant 
intravesical treatment. 
BIOCHEMICAL PARAMETERS 
• The role of carcinoembryonic antigen (CE A) has been 
reviewed by Ackermann (45) who reported a wide range of 
CEA levels in the blood of patients suffering from bladder 
cancer. This test did not find any wide-spread clinical appli- 
cation, because of its low sensitivity and low specificity in 
cases of urothelial bladder cancer. Increased levels of serum 
carbohydrate antigen 19.9 might be important in monitoring 
the natural history of bladder cancer; however, its value as a 
prognostic indicator is also still questionable (46). A promis- 
ing tumor marker is the tissue polypeptide antigen (TPA). 
Except for tumor diagnosis, plasma TPA concentration has 
showed a good correlation with tumor progression as well as 
regression after treatment in urothelial bladder cancer (47). 
Carbin et al (48) later suggested the important role of urinary 
TPA as an indicator of bladder cancer recurrence. 
OHCOGEMES AMD TUMOR SUPPRESSOR GENES 
• It is well accepted that defects at a number of tran- 
scriptional and posttranscriptional steps in a gene product may 
be involved in the appearance of malignancy or a metastatic 
phenotype. These include transcript initiation, transcriptional 
proof-reading, pre-mRNA splicing, and mRNA export from 
the nucleus to the cytoplasm. Examples of oncogenes and tu- 
mor suppressor genes used as prognostic markers in bladder 
tumors are presented below. 
•         c-erbT$-2 oncogene 
The c-erbB-2 gene product is a transmembrane receptor pro- 
tein with partial homology to EGFR. Amplification or 
overexpression of the c-erbB-2 gene have been reported to 
correlate with poor prognosis in human breast, gastric, and 
ovarian cancer. Recently, the c-erbB-2 protein was found to 
be expressed frequently in the urinary bladder carcinoma as 
well. A few studies have confirmed that the expression rate of 
c-erbB-2 protein corresponded to the advancement of tumor 
grade and stage and correlated with patient survival (49-51). 
Tumors without c-erbB-2 expression had a higher risk of re- 
currence, and that was independent of the stage and grade of 
bladder cancer. The 5-year disease-free survival rate is 48.5% 
for patients with c-erbB-2 -negative tumors vs 9.7 % for those 
with c-erbB-2 -positive tumors (50). On the contrary, the im- 
munohistochemical demonstration of c-erbB-2 protein overex- 
pression in paraffin-embedded archival material had no prog- 
nostic value over already established predictors in transitional 
cell bladder cancer (52). Therefore, a better understanding of 
the regulatory mechanisms and physiological properties of 
c-erbB-2 protein in the urothelium is required and its precise 
predictive role in bladder cancer cases should be further clari- 
fied. 
•         p53 gene 
The tumor suppressor p53 gene is located in chromosome 
17pl3-l and encodes for a 53 kD nuclear protein (p53). The 
role of p53 is to prevent damage to cells via DNA repair, and 
to induce apoptotic cell death in case of irreversible damage. 
Accordingly, alteration of the p53 tumor suppressor gene is 
the most common genetic abnormality found in human can- 
cer, including bladder cancer. Immunohistochemical detect- 
ability of p53 is associated with early events in the malignant 
evolution, occurring in 48 % of cases of bladder carcinoma in 
situ (53). Other reports show that there are different patterns 
of staining for p53 protein, according to which tumors may be 
divided into group A, in which no more than 20 % tumor cells 
show positive nuclear staining, and group B, with 20 % or 
more nuclear immunoreactivity. Patients in group B have a 
higher probability of disease progression and a significantly 
lower progression-free interval (54-57). Positive staining for 
p53 is found more frequently in poorly differentiated and in 
invasive tumors (58,59). Expression of p53 is also closely as- 
sociated with tumor recurrences. A correlation between mu- 
tated p53 and poor survival in the whole group of patients is 
found as well (60). There are however great variabilities in 
tumor staining for p53, even with the same antibody (61). The 
heterogeneity of p5 3-positive cell distribution in the tumors 
indicates potential for significant sampling errors. The use of 
immunohistological p53 expression as a discriminating prog- 
nostic indicator in pTl transitional cell cancer merits further 
attention. If the high prognostic value of p53 mutations in 
SET is confirmed in larger prospective trials, more aggressive 
therapeutic strategies could be discussed for patients with p53 
mutations in their tumor specimens. Correlative studies of 
expression of p53, a stimulator of apoptosis, and bcl-2, a sup- 
pressor of apoptosis (see Arumae in this volume of Biomedi- 
cal Reviews), may provide additional prognostic significance 
in bladder cancer. 
•         p21 gene 
Abnormal activation of ras oncogene and the expression of its 
product p21, a 21 kD protein, are present in a number of hu- 
man tumors. Using an ABC immunoenzymatic staining tech- 
nique and a p21 specific monoclonal antibody, Miao et al (62) 
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detected that the morbidity rate due to tumor recurrence in 
p21-positive patients was only 9 %, whereas in p21-negative 
patients it was 67 %. 
•        MDM2gene 
The human MDM2 gene was recently cloned and located in 
chromosome 12ql3-14. There is a striking association between 
MDM2 overexpression and low-stage, low-grade bladder tumors, 
and with p53 overexpression as well (63). So, simultaneous 
immunostaining of MDM2 and p53 may be an important diag- 
nostic and prognostic method in patients with bladder cancer. 
•         Retinoblastoma gene 
The retinoblastoma tumor suppresor gene (RB1) is located in 
chromosome 13ql4, and its product is a 110 kD cell cycle- 
related nuclear protein (pi 10
Ml
). Interestingly, pi 10
RB1
, known 
to be involved information of retinoblastomas, is also present 
in other tumor tissues, including bladder cancer (64). pi W
mi 
expression was found to be independent of other known prog- 
nostic variables (65,66). A low value for the fraction of RB1 
protein-positive nuclei is related to a large fraction in S phase, 
high mitotic index and overexpression of EGFR and mutated 
p53. In an univariate survival analysis altered expression of 
RB1 protein and low frequency (< 50 %) of RB1 protein-posi- 
tive nuclei predicts poor outcome. These results show that 
RB1 gene, as well asmutation in p53 gene, participate in the 
growth regulation of human bladder cancer cells in vivo and 
accordingly modify the prognosis. 
•         Multidrug resistance gene 
Resistance of malignant cells to cytotoxic agents is often a 
limiting factor to successful chemotherapy. The classical 
multidrug resistance (MDR) is characterised by overexpression 
of a 170 kD transmembrane, transporter glycoprotein named 
P-glycoprotein (gp!70). The latter acts like a drug extruding 
pump reducing accumulation of cytotoxic agents inside ma- 
lignant cells, rndrl gene expression is significantly higher in 
poorly differentiated high-grade tumors, than in well and mod- 
erately differentiated, low-grade tumors (67). Still no evidence 
is found, however, to implicate mdrl overexpression as a pre- 
dictor of tumor recurrence or progression in SET. 
•         Nucleolar organisers 
Nucleolar organisers (NOR) are intranucleolar segments of 
DNA coding for ribosomal RNA. The argyrophilic proteins 
associated with NOR (AgNOR) allow them to be cytolabelled 
on paraffin sections. The number of NOR expression (NOR 
index) is correlated with cellular proliferation and has a diag- 
nostic and prognostic value in neoplastic disease. The NOR 
index is 4.54 for normal urothelium, 5.89 for non-invasive 
superficial tumors, 7.33 for invasive superficial rumors, and 
9.75 for invasive recurrences (68). These results demonstrate 
an increase in nucleolar argyrophilia with invasion and indi- 
cate the invasive potential of SET which are initially homoge- 
neous for stage and grade. Lipponen et al (69) assessed the 
predictive value of silver stained NOR in 229 patients with 
transitional cell cancer, followed up for over 10 years. The 
increased number of NOR in pTa-pTl SET correlated signifi- 
cantly with the recurrence rate and tumor progression and with 
the patient survival. In a multivariate analysis, AgNOR pre- 
dict progression independently. 
GENETIC ABNORMALITIES 
• Some chromosomal abnormalities play a certain role 
in the development of bladder tumors. Bladder cancer with 
normal karyotypes remains superficial and continues to ex- 
hibit a non-aggressive course, while patients whose tumors 
have an abnormal karyotype at the time of initial diagnosis, 
express a much more aggressive course that ultimately devel- 
ops into invasive disease (70,71). 
CD44 GENE TRANSCRIPTS 
• Recently, a great advance has been made in understand- 
ing alternative splicing, the RNA processing mechanism 
whereby the primary transcript (pre-mRNA) of a gene is pro- 
cessed by spliceosomes, removing introns, and adjoining spe- 
cific combinations of exons, toyeild different copies of mRNA, 
leading to the expression of multiple proteins from a single 
gene, i.e. alternatively spliced gene products. The most no- 
table example to date for attributing pathological consequences 
to the expression of altenatively spliced gene products is the 
role of the cell adhesion molecule CD44 in tumor growth, 
invasion, and metastasis. The CD44 gene is 50-60 kbp long, 
resides on chromosome 11, and is composed of at least 20 
exons, ten or more of which can be alternatively spliced to 
produce various isoforms. Matsumura et al (72,73) described 
for the first that exfoliated tumor cells in the urine of bladder 
cancer patients exibited CD44 transcripts having retained the 
variant intron 9. The abnormal products of this gene can be 
detected with the technique of reverse transcription (RT)-poly- 
merase chain reaction (PCR) followed by monoclonal or 
polyclonal antibodies to peptide sequences encoded by the vari- 
ant exons of the gene. In effect, intron retention hypothesis 
(73) could form the basis for a new, specific and effective non- 
invasive diagnostic and prognostic test for the bladder cancer. 
CONCLUSIONS 
• It is evident that various biological tumor markers, whose 
expression correlates with the recurrence and progression rates   
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and patient survival, may be used as objective prognosticates 
of the malignant evolution of SET. Unfortunately, a complete 
consensus concerning the clinical application of most of the 
already established tumor markers does not exist yet. The 
controversy available in the published results of clinical trials 
is most probably due to the limited number of the patients, 
incorrect patient selection, lack of standardized histochemi- 
cal techniques, etc. That is why most of the aforementioned 
biological tumor markers still are at a preclinical phase of 
application and cannot be used alone as basic criteria when 
the treatment schedules for initial therapy and metaphylaxis 
have to be determined. Coordinated studies using selected 
monoclonal immunostaining, RT-PCR, in situ hybridization, 
and microwave antigen retrieval methods (74) may further be 
organized, searching for state-of-the-art tumor markers in blad- 
der cancer. Together with the rapid development of medical 
genetics, leading to a more profound knowledge of the human 
genome and of the molecular aspects of cancerogenesis, that 
will allow an widespread clinical use of biological tumor mark- 
ers in close future. In such a way, the final goal of the prog- 
nostic assessment - an improvement of the individual coun- 
selling, may be achieved. Associated with the clinical appli- 
cation of new, more efficient, local chemotherapeutics and 
immunomodulators and optimal therapeutic schedules, that 
will lead to a significant reduction of the recurrences and tu- 
mor progression in cases of bladder cancer. Biological tumor 
markers seem to be therefore some of the most perspective 
arms in the eternal fight against this insidious malignancy. 
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